ANALISE ESTRUTURADA SISTEMAS CHRIS GANE PDF
19 nov. Transcript of Análise Estruturada Um estudo não publicado sugere que a modificação de um sistema que utilize projeto estruturado chega a. Structured Systems Analysis: Tools and Techniques by Chris Gane (). by Chris Análise Estruturada De Sistemas (Em Portuguese do Brasil). 11 abr. Chris Gane Et All. 7. Análise Estruturada e Especificação de Sistema Tom DeMarco. 8. Applied Software Measurement, Assuring.
|Published (Last):||24 April 2005|
|PDF File Size:||2.88 Mb|
|ePub File Size:||8.94 Mb|
|Price:||Free* [*Free Regsitration Required]|
Branch retinal vein occlusion associated with quetiapine fumarate. Directory of Open Access Journals Sweden. Full Text Available Abstract Background To report a case of branch retinal vein occlusion in a young adult with bipolar mood disorder treated with quetiapine fumarate.
Case Presentation A 29 years old gentleman who was taking quetiapine fumarate for 3 years for bipolar mood disorder, presented with sudden vision loss. He was found to have a superior temporal branch retinal vein occlusion associated with hypercholesterolemia. Conclusion Atypical antipsychotic drugs have metabolic side effects which require regular monitoring and prompt treatment.
The effect of pH, buffer capacity and ionic strength on quetiapine fumarate release from matrix tablets prepared using two different polymeric blends. A series of solubility and in vitro dissolution studies was then carried out using media that simulate the gastric and intestinal fluids sistrmas cover the physiological pH, buffer capacity and ionic strength range of the GIT.
Solubility studies revealed that QF exhibits a typical snalise base pH-dependent solubility profile and that the solubility of QF increases with increasing the buffer capacity and ionic strength of the media.
Results highlight the importance of studying the physiological variables along the GIT in designing controlled release formulations for more predictive in vitro-in vivo correlations.
Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders. The atypical antipsychotic quetiapine fumarate is available both as an immediate release IR and as an extended release XR formulation allowing flexibility of dosing for individual patients.
Approved uses of quetiapine XR include the treatment of schizophrenia including maintenance therapy for prevention of relapse, the treatment of bipolar disorder manic and depressive episodes, and the prevention of recurrence in patients with bipolar disorder who respond to quetiapine XR.
This narrative review provides an update on quetiapine XR in these indications. The pharmacological profile of quetiapineincluding a moderate affinity for dopamine D2 receptors and higher affinity for serotonin 5-hydroxytryptophan 5-HT2A receptors, may explain its broad efficacy and low propensity for extrapyramidal symptoms EPS.
seroquel quetiapine fumarate: Topics by
The XR formulation has similar bioavailability but prolonged plasma levels compared with the IR formulation, allowing for etsruturada frequent once-daily dosing. Clinical studies have confirmed the efficacy of quetiapine XR in relieving the acute symptoms of schizophrenia during short-term trials, and reducing the risk for relapse in long-term studies.
Direct switching from the IR formulation to the same dose of the XR formulation did not reveal any loss of efficacy or tolerability issues, and switching patients to quetiapine XR from conventional or other atypical antipsychotics for reasons of insufficient efficacy or tolerability also proved to be beneficial and generally well tolerated.
In bipolar disorder, quetiapine XR has also proven effective in relieving acute depressive and manic symptoms. Adverse events with quetiapine XR in patients with either schizophrenia or bipolar disorder are similar to those associated with the IR formulation, the most common being sedation, dry mouth, somnolence, dizziness, and headache. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate quetiapine XR monotherapy in patients with major depressive disorder.
To evaluate the efficacy and tolerability of once-daily extended release quetiapine fumarate quetiapine XR monotherapy in patients with major depressive disorder MDD. There were no significant differences in secondary end points versus placebo, with the exception of week-eight change in PSQI global score quetiapine XR, The purpose of the research was to assess multimodal in vitro methodology for further bioequivalence study risk minimization.
Principal results of the study are as follows: Major conclusions are as follows: Titrimetric and spectrophotometric assay of quetiapine fumarate QTF using perchloric acid and acetic acid as reagents are described. The first method method A is a non-aqueous titrimetric method and is based on the titration of QTF in glacial acetic acid with 0. In the second method method B, QTF has been measured in 0. The apparent molar absorptivity was calculated to be 4.
Accuracy and precision of the assays were determined by computing the intra-day and inter-day variations at three different levels of QTF. Effective management of schizophrenia remains a significant clinical challenge. While antipsychotic medications have proven efficacy in this disease, there remains an opportunity to further improve symptom control and long-term relapse prevention.
Also, a number of factors, including tolerability and complex dosing regimens, can result in nonadherence to medication. Quetiapine is an atypical antipsychotic with proven efficacy and an established tolerability profile in schizophrenia. The once-daily extended-release formulation quetiapine XR offers a simplified dosing regimen and titration schedule.
Furthermore, an investigation in which stable patients switched from the immediate-release formulation quetiapine IR to dstruturada XR showed that quetiapine XR is generally well tolerated and has no loss of efficacy compared with quetiapine IR. In patients who experienced insufficient efficacy or poor tolerability on their previous antipsychotic, switching to quetiapine XR significantly improved efficacy compared with the previous treatment.
In conclusion, quetiapine XR is an effective and generally well tolerated treatment for schizophrenia. Furthermore, once-daily dosing aalise improve patient adherence, which may impact positively on patient outcomes.
Spectrophotometric determination of quetiapine fumarate in pharmaceuticals and human urine by two charge-transfer complexation reactions. Full Text Available Two simple, rapid and accurate spectrophotometric procedures ganf proposed for the determination of quetiapine fumarate QTF in pharmaceuticals and in spiked human urine. The coloured charge transfer complexes produced exhibit absorption maxima at and nm, in method A and method B, respectively. The experimental conditions such as reagent concentration, reaction solvent and time have been carefully optimized to achieve the maximum sensitivity.
VIAF ID: 25145610 (Personal)
The calculated molar absorptivity values are 1. The stoichiometry of the reaction in both cases was accomplished adopting the limiting logarithmic method and was found to be 1: The accuracy and precision of the methods were evaluated on intra-day and inter-day basis. The proposed methods were successfully applied for the determination of QTF in pharmaceutical formulations and spiked human urine. The objective of the present investigation was to optimize and develop quetiapine fumarate QF loaded chitosan nanoparticles QF-NP by ionic gelation method using Box-Behnken design.
Three independent variables viz. Optimized formula of QF-NP was selected from the design space which was further evaluated for physicochemical, morphological, solid state characterization, nasal diffusion and in-vivo distribution for brain targeting following non-invasive intranasal administration.
Neither toxicity nor structural damage on nasal mucosa was observed upon histopathological examination. Overall, the above finding shows promising results in the area of developing non-invasive intranasal route as an alternative to oral route for brain delivery. Edema associated with quetiapine. Background Edema associated with quetiapine has been described in only one case report to date and represents a potentially serious adverse reaction.
Methods We present a case series of three patients who developed bilateral leg edema following initiation of quetiapine. Results One of these patients had a recurrence of edema with subsequent rechallenge.
Another patient developed quetiapine -induced edema following a prior episode of olanzapine-induced edema. All the cases present a compelling temporal relationship between the drug challenge and the adverse event.
Conclusions Prompt recognition and intervention with discontinuation of the offending agent is important for this potentially serious, seemingly idiosyncratic, vascular complication. Quetiapine monotherapy for bipolar depression. Bipolar depression is more common, disabling, and difficult-to-treat than the manic and hypomanic phases that define bipolar disorder.
The current practice is that mood stabilizers are initiated first as monotherapies; however, the antidepressant efficacy of lithium and valproate is modest at best. Within this context the role of atypical antipsychotics is being evaluated. The combination of olanzapine and the antidepressant fluoxetine was the first treatment to receive regulatory approval in the US specifically for bipolar I depression.
Both studies demonstrated that two doses of quetiapine mg and mg given once daily at bedtime were significantly more effective than placebo, with no increased risk of patients switching into mania. Pooling the two studies, quetiapine was effective for both bipolar I and bipolar II depressions and for patients with and without a history of rapid cycling.
The two doses were comparably effective in both studies. Although the efficacy of quetiapine monotherapy has been established, much additional research is necessary. Further studies are needed to more fully investigate dose-response relationships and comparing quetiapine monotherapy to other mood stabilizers.
Recurrent Priapism from Therapeutic Quetiapine.
Full Text Available Priapism is rarely related to use of non-erectile related medications. The objective was to educate about the multiple possible causes of priapism and to provide treatment recommendations for the different types of priapism. We present the case of a 43 year-old African American male with a history of schizoaffective disorder who presented to our emergency department multiple times over a three year period with priapism, each episode related to the ingestion of quetiapine.
Following penile aspiration and intercavernosal injection of phenylephrine, this patient had resolution of his priapism. This case demonstrates an unusual case of recurrent priapism. Full Text Available A rapid and sensitive capillary zone electrophoresis CZE method with field enhanced sample injection FESI was cchris and validated for the determination of quetiapine fumarate in beagle dog plasma, with a sample pretreatment by LLE in well deep format plate.
The optimum separation was carried out in an uncoated The electrophoretic analysis was performed by 50 mM phosphate at pH 2. The detection wavelength was curis. Under these optimized conditions, FESI with acetonitrile enhanced the sensitivity of quetiapine about 40—50 folds in total.
The method was suitably validated with respect to stability, specificity, linearity, lower limit of quantitation, accuracy, precision and extraction recovery.
The intra- and inter-day precisions for the assay were within 4. The method represents the first application of FESI-CZE to the analysis of quetiapine fumarate in beagle dog plasma after oral administration. Fumaric acid production by fermentation. Abstract The potential of fumaric acid as a raw material in the polymer industry and the increment of cost of petroleum-based fumaric acid raises interest in fermentation processes for production of this compound from renewable resources.
Quetiapine versus other atypical antipsychotics for schizophrenia. It is not clear how the effects of the various second generation antipsychotic drugs differ. Objectives To evaluate the effects of quetiapine compared with other second generation antipsychotic drugs for people with schizophrenia and schizophrenia-like psychosis.
Search methods We searched the Cochrane Schizophrenia Group Trials Register Aprilinspected references of all identified studies, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. Selection criteria We included all randomised control trials comparing oral quetiapine with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis.
Data collection and analysis We extracted data independently. For continuous data, extruturada calculated weighted mean differences WMD ssitemas based on a random-effects model. Main results The review sstemas includes 21 randomised control trials RCTs with participants. These trials provided data on four comparisons – quetiapine versus clozapine, olanzapine, risperidone or ziprasidone.
A major limitation to all findings is the high number of participants leaving studies prematurely Efficacy data favoured analuse and risperidone compared with quetiapine PANSS total score versus olanzapine: Fumaric acid and its calcium, ferrous, magnesium, potassium, and sodium salts may be safely used A retrospective record review and assessment of cost of quetiapine